226H細(xì)胞

數(shù)量： 大量

是否是腫瘤細(xì)胞： 0

物種來(lái)源： 小鼠

細(xì)胞形態(tài)： **樣

**類型： IgG1; kappa light chain

運(yùn)輸方式： 凍存運(yùn)輸

生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)

ATCC Number： HB-12592?

Designations: 226H

226H細(xì)胞Depositors: ICOS Corporation

Isotype: IgG1; kappa light chain

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)

Morphology: lymphoblast

Cellular Products: immunoglobulin; monoclonal antibody; against alphaD subunit of rat beta2 (alphaDbeta2) integrin

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. 226H細(xì)胞Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Comments: Animals were immunized with purified rat alphaD subunit. [56177]

Spleen cells were fused with NS-1 mouse myeloma cells.

This antibody is specific for the rat subunit integrin alphaD.

It may be used to inhibit inflammation at the site of a central nervous system injury.

Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 85%; heat-inactivated fetal bovine serum, 15%

Temperature: 37.0°C

Subculturing: 226H細(xì)胞Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)

Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.

Preservation: Culture medium supplemented with an additional 50% heat-inactivated fetal bovine serum and 10% DMSO

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

References: 56177: Gallatin WM, Van der Vieren M. Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies. US Patent 6,251,395 dated Jun 6 2001

57779: Mabon PJ, et al. Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment. Exp. Neurol. 166: 52-64, 2000. 226H細(xì)胞PubMed: 11031083